Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines
Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with informatio...
Gespeichert in:
Veröffentlicht in: | American journal of health-system pharmacy 2022-06, Vol.79 (12), p.993-1005 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1005 |
---|---|
container_issue | 12 |
container_start_page | 993 |
container_title | American journal of health-system pharmacy |
container_volume | 79 |
creator | Pritchard, Daryl Patel, Jai N Stephens, Lindsay E McLeod, Howard L |
description | Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Information from CPIC guidelines and the FDA Table of Pharmacogenetic Associations do not have a high level of concordance. Many drugs mentioned in CPIC guidelines are not listed in the FDA table and vice versa, and the same gene-drug association and dosing recommendation was reported for only 5 of the 126 drugs included in either source. Furthermore, classification of drugs in specific sections of the FDA table does not correlate well with CPIC-assigned or provisionally assigned clinical actionability levels. The Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation levels are generally high for drugs mentioned in CPIC guidelines. PharmGKB clinical annotation levels are often unassigned or are lower level for drugs listed on the FDA table but not in CPIC guidelines. These differences may be due in part to FDA having access to PGx information that is unavailable in published literature and/or because PGx classifications are based on criteria other than clinical actionability.
There are important differences between the PGx information presented in the FDA Table of Pharmacogenetic Associations and in CPIC guidelines. FDA and CPIC have different perspectives when evaluating PGx associations and use different approaches and information resources when considering clinical validity related to specific medicines. Understanding how information sources developed by each group differ and can be used together to form a holistic view of PGx may be helpful in increasing adoption of these information sources in practice. |
doi_str_mv | 10.1093/ajhp/zxac064 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9171570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634850470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-cbb80a07ef0638732ba16e693833d1a2daca43a7cca7bc97c6f39d42cae1d6943</originalsourceid><addsrcrecordid>eNpdkctLxDAQxoMouj5uniVHD1YnSZ8XYalPWNCDnsM0TXcjbVOTVtS_3u5DUU8zw_zmmw8-Qo4ZnDPIxAW-LLqLz3dUEIdbZMIiEQU8A9gee0iygEPK98i-9y8AjKcQ75I9EXEBIUsn5DO3TYfOeNtSW9Gbqyl9wqLWy-Fxga5BZee61b1RdOq9VQZ7Y1tPsS1pXpvWKKz_k57eN12tG932K5rm44V1vRkaOh9Mqcc77Q_JToW110ebekCeb66f8rtg9nB7n09ngRJp2AeqKFJASHQFsUgTwQtksY4zkQpRMuQlKgwFJkphUqgsUXElsjLkCjUr4ywUB-RyrdsNRaNLNbpyWMvOmQbdh7Ro5N9NaxZybt9kxhIWJTAKnG4EnH0dtO9lY7zSdY2ttoOXPBZhGkG4Qs_WqHLWe6ernzcM5DIuuYxLbuIa8ZPf1n7g73zEF7MQlt0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634850470</pqid></control><display><type>article</type><title>Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Pritchard, Daryl ; Patel, Jai N ; Stephens, Lindsay E ; McLeod, Howard L</creator><creatorcontrib>Pritchard, Daryl ; Patel, Jai N ; Stephens, Lindsay E ; McLeod, Howard L</creatorcontrib><description>Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Information from CPIC guidelines and the FDA Table of Pharmacogenetic Associations do not have a high level of concordance. Many drugs mentioned in CPIC guidelines are not listed in the FDA table and vice versa, and the same gene-drug association and dosing recommendation was reported for only 5 of the 126 drugs included in either source. Furthermore, classification of drugs in specific sections of the FDA table does not correlate well with CPIC-assigned or provisionally assigned clinical actionability levels. The Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation levels are generally high for drugs mentioned in CPIC guidelines. PharmGKB clinical annotation levels are often unassigned or are lower level for drugs listed on the FDA table but not in CPIC guidelines. These differences may be due in part to FDA having access to PGx information that is unavailable in published literature and/or because PGx classifications are based on criteria other than clinical actionability.
There are important differences between the PGx information presented in the FDA Table of Pharmacogenetic Associations and in CPIC guidelines. FDA and CPIC have different perspectives when evaluating PGx associations and use different approaches and information resources when considering clinical validity related to specific medicines. Understanding how information sources developed by each group differ and can be used together to form a holistic view of PGx may be helpful in increasing adoption of these information sources in practice.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.1093/ajhp/zxac064</identifier><identifier>PMID: 35230418</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Humans ; Pharmacogenetics ; Pharmacogenomic Testing ; United States ; United States Food and Drug Administration</subject><ispartof>American journal of health-system pharmacy, 2022-06, Vol.79 (12), p.993-1005</ispartof><rights>American Society of Health-System Pharmacists 2022.</rights><rights>American Society of Health-System Pharmacists 2022. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-cbb80a07ef0638732ba16e693833d1a2daca43a7cca7bc97c6f39d42cae1d6943</citedby><cites>FETCH-LOGICAL-c384t-cbb80a07ef0638732ba16e693833d1a2daca43a7cca7bc97c6f39d42cae1d6943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35230418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pritchard, Daryl</creatorcontrib><creatorcontrib>Patel, Jai N</creatorcontrib><creatorcontrib>Stephens, Lindsay E</creatorcontrib><creatorcontrib>McLeod, Howard L</creatorcontrib><title>Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Information from CPIC guidelines and the FDA Table of Pharmacogenetic Associations do not have a high level of concordance. Many drugs mentioned in CPIC guidelines are not listed in the FDA table and vice versa, and the same gene-drug association and dosing recommendation was reported for only 5 of the 126 drugs included in either source. Furthermore, classification of drugs in specific sections of the FDA table does not correlate well with CPIC-assigned or provisionally assigned clinical actionability levels. The Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation levels are generally high for drugs mentioned in CPIC guidelines. PharmGKB clinical annotation levels are often unassigned or are lower level for drugs listed on the FDA table but not in CPIC guidelines. These differences may be due in part to FDA having access to PGx information that is unavailable in published literature and/or because PGx classifications are based on criteria other than clinical actionability.
There are important differences between the PGx information presented in the FDA Table of Pharmacogenetic Associations and in CPIC guidelines. FDA and CPIC have different perspectives when evaluating PGx associations and use different approaches and information resources when considering clinical validity related to specific medicines. Understanding how information sources developed by each group differ and can be used together to form a holistic view of PGx may be helpful in increasing adoption of these information sources in practice.</description><subject>Humans</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenomic Testing</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctLxDAQxoMouj5uniVHD1YnSZ8XYalPWNCDnsM0TXcjbVOTVtS_3u5DUU8zw_zmmw8-Qo4ZnDPIxAW-LLqLz3dUEIdbZMIiEQU8A9gee0iygEPK98i-9y8AjKcQ75I9EXEBIUsn5DO3TYfOeNtSW9Gbqyl9wqLWy-Fxga5BZee61b1RdOq9VQZ7Y1tPsS1pXpvWKKz_k57eN12tG932K5rm44V1vRkaOh9Mqcc77Q_JToW110ebekCeb66f8rtg9nB7n09ngRJp2AeqKFJASHQFsUgTwQtksY4zkQpRMuQlKgwFJkphUqgsUXElsjLkCjUr4ywUB-RyrdsNRaNLNbpyWMvOmQbdh7Ro5N9NaxZybt9kxhIWJTAKnG4EnH0dtO9lY7zSdY2ttoOXPBZhGkG4Qs_WqHLWe6ernzcM5DIuuYxLbuIa8ZPf1n7g73zEF7MQlt0</recordid><startdate>20220607</startdate><enddate>20220607</enddate><creator>Pritchard, Daryl</creator><creator>Patel, Jai N</creator><creator>Stephens, Lindsay E</creator><creator>McLeod, Howard L</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220607</creationdate><title>Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines</title><author>Pritchard, Daryl ; Patel, Jai N ; Stephens, Lindsay E ; McLeod, Howard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-cbb80a07ef0638732ba16e693833d1a2daca43a7cca7bc97c6f39d42cae1d6943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Humans</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenomic Testing</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pritchard, Daryl</creatorcontrib><creatorcontrib>Patel, Jai N</creatorcontrib><creatorcontrib>Stephens, Lindsay E</creatorcontrib><creatorcontrib>McLeod, Howard L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pritchard, Daryl</au><au>Patel, Jai N</au><au>Stephens, Lindsay E</au><au>McLeod, Howard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2022-06-07</date><risdate>2022</risdate><volume>79</volume><issue>12</issue><spage>993</spage><epage>1005</epage><pages>993-1005</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>Healthcare professionals need a clear understanding of information about gene-drug interactions in order to make optimal use of pharmacogenetic (PGx) testing. In this report, we compare PGx information in the US Food and Drug Administration (FDA) Table of Pharmacogenetic Associations with information presented in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Information from CPIC guidelines and the FDA Table of Pharmacogenetic Associations do not have a high level of concordance. Many drugs mentioned in CPIC guidelines are not listed in the FDA table and vice versa, and the same gene-drug association and dosing recommendation was reported for only 5 of the 126 drugs included in either source. Furthermore, classification of drugs in specific sections of the FDA table does not correlate well with CPIC-assigned or provisionally assigned clinical actionability levels. The Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation levels are generally high for drugs mentioned in CPIC guidelines. PharmGKB clinical annotation levels are often unassigned or are lower level for drugs listed on the FDA table but not in CPIC guidelines. These differences may be due in part to FDA having access to PGx information that is unavailable in published literature and/or because PGx classifications are based on criteria other than clinical actionability.
There are important differences between the PGx information presented in the FDA Table of Pharmacogenetic Associations and in CPIC guidelines. FDA and CPIC have different perspectives when evaluating PGx associations and use different approaches and information resources when considering clinical validity related to specific medicines. Understanding how information sources developed by each group differ and can be used together to form a holistic view of PGx may be helpful in increasing adoption of these information sources in practice.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35230418</pmid><doi>10.1093/ajhp/zxac064</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-2082 |
ispartof | American journal of health-system pharmacy, 2022-06, Vol.79 (12), p.993-1005 |
issn | 1079-2082 1535-2900 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9171570 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
subjects | Humans Pharmacogenetics Pharmacogenomic Testing United States United States Food and Drug Administration |
title | Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T04%3A53%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20FDA%20Table%20of%20Pharmacogenetic%20Associations%20and%20Clinical%20Pharmacogenetics%20Implementation%20Consortium%20guidelines&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Pritchard,%20Daryl&rft.date=2022-06-07&rft.volume=79&rft.issue=12&rft.spage=993&rft.epage=1005&rft.pages=993-1005&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.1093/ajhp/zxac064&rft_dat=%3Cproquest_pubme%3E2634850470%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634850470&rft_id=info:pmid/35230418&rfr_iscdi=true |